The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (ILD), acute and/or severe (may produce the ARDS pattern)
Publications
Rituximab-Induced Interstitial Lung Disease: A Stitch in Time Saved Nine.
Cureus. 2022;14(7):e27088
Rituximab associated pneumonitis in antineutrophil cytoplasmic antibody-associated vasculitis.
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2012;18(1):39-41
Adverse pulmonary reactions associated with the use of monoclonal antibodies in cancer patients.
Respiratory medicine. 2012;106(3):443-50
Pulmonary toxicities from targeted therapies: a review.
Targeted oncology. 2011;6(4):235-43
Huang YC, Liu CJ, Liu CY, Pai JT, Hong YC, Teng HW, Hsiao LT, Chao TC, Gau JP, Liu JH, Hsu HC, Chiou TJ, Chen PM, Yu YB, Tzeng CH
Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma.
Annals of hematology. 2011;90(10):1145-51
Severe respiratory adverse events associated with rituximab infusion.
Pediatric nephrology (Berlin, Germany). 2010;25(6):1193
Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients.
Annals of internal medicine. 2006;144(7):505-9